SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community discusses its potential as a safe haven amid government shutdown concerns and anticipation for a historically strong October. Bullish sentiment is fueled by the expectation of institutional adoption and potential price surges, while some traders remain cautious, watching key resistance levels and potential market corrections.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst a government shutdown, sparking heated debates about healthcare for undocumented immigrants and the release of the Epstein files. The community is divided, with opinions clashing over political affiliations, economic policies, and the role of government. Discussions range from concerns about the shutdown's impact to accusations of political corruption and influence.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amidst concerns about a potential government shutdown and its possible impact on markets. While some traders anticipate a market dip due to the shutdown, others point to historical data suggesting previous shutdowns led to market gains, creating mixed community sentiment. Discussions also revolve around inflation, potential economic impacts, and political reactions to the shutdown.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following a surprise revenue increase and earnings beat, fueling investor optimism about the company's turnaround efforts despite ongoing concerns about tariffs and weakness in the Chinese market. Bullish sentiment is growing, with analysts upgrading price targets and the community anticipating a potential short squeeze. Discussions also focus on the evolving competitive landscape and Nike's strategic collaborations, such as the partnership with SKIMS.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending amid a recent pullback, leading to divided opinions on potential bottom-fishing versus further downside. Community members are actively discussing short squeeze opportunities, potential support levels, and the impact of broader market factors like interest rates and a possible government shutdown. Some traders point to a BTIG analyst report raising concerns about delinquencies as a catalyst for the stock's recent struggles.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as the stock experiences volatility, with community members debating whether to buy the dip or anticipate further decline. Discussions include potential support levels and upcoming events, while some traders point to positive analyst ratings and long-term growth potential despite near-term concerns. A potential hearing in Congress is also on investors' radars.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE.X is trending as the community rallies behind it as a potential mascot for xAI and Grok, with some speculating about Elon Musk's interest. Community members highlight the strong community, zero taxes, and burned liquidity as reasons to be bullish. There is also discussion around the existence of scam versions of the token.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending downwards as the community discusses potential competition from prediction markets like Kalshi and Robinhood, which some believe could draw users away from traditional sports betting. Investors are also concerned about the company's leadership and its ability to innovate in the face of increasing competition. Some senators are expressing concerns about the legality of event contracts used for sports betting.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst is trending as investors digest the implications of the completed sale of its European business, with community discussions focused on whether this move signals a potential acquisition of the company or a shift in strategic direction. Some express concern about management decisions and the stock's performance relative to its peers, while others remain optimistic about the long-term potential and upcoming data readouts. Chatter also revolves around the impact of potential competition from new drugs in the HAE market.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending amid news of upcoming hardware and AI product launches, sparking speculation about a potential turnaround. The community is actively discussing the stock's potential for a short squeeze and comparing it to other turnaround stories, like Carvana. Discussions also include the impact of potential price increases and the company's move into profitability.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR  (ONC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Surges 4.0%: Is This an Indication of Further Gains?

BeOne Medicines Ltd. - Sponsored ADR  (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven by encouraging results from a late-stage cancer drug trial.The company’s sponsor, Akeso, announced that a phase 3 trial evaluating Summit’s drug, ivonescimab, in combination with chemotherapy, met its primary endpoint of progression-free survival in patients with advanced squamous non-small cell lung cancer (NSCLC).Akeso conducted the study across multiple centers in China, comparing the combination against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.An independent data monitoring committee found that the ivonescimab arm demonstrated statistically significant and clinically meaningful improvement.Summit plans to present the full dataset from the trial at a major medical conference later this year.&nbsp;On Stocktwits, sentiment for Summit rose further within 'extremely bullish' levels amid a 507% spike in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SMMT_sentiment_and_message_volume_as_of_April_23_png_a70ccf1959.webp" alt="SMMT sentiment and message volume as of April 23.png" width="1318" height="316"><figcaption>SMMT sentiment and message volume as of April 23. | source: Stocktwits</figcaption></figure>One bullish watcher urged investors to watch out for a "short squeeze up to $40."<stembedurl>https://stocktwits.com/BooEmmy/message/612403946</stembedurl>"The path is rising. And the journey has only just begun," said another.<stembedurl>https://stocktwits.com/Teluride/message/612467520</stembedurl>Summit is enrolling patients in a separate multiregional study pitting the same combination against pembrolizumab (Merck's Keytruda) plus chemo in first-line metastatic NSCLC. Early trial results from China have already shown promising results.The company also boosted investor enthusiasm after joining a clinical trial&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smmt-retail-chatter-explodes-on-pfizer-trial-pact/chdEqVTRx8">collaboration</a> with Pfizer in February.Summit's stock has surged by over 84% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Equity

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.


BeiGene to Present at Upcoming Investor Conferences

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside...

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial...

<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks&nbsp;while lifting retail sentiment.The clinical-stage immunotherapy company announced a collaboration and supply agreement with BeiGene to conduct a confirmatory Phase 3 clinical trial.&nbsp;The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for patients with advanced or metastatic non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy.According to ImmunityBio, multiple Phase 1 and 2 studies have already shown prolonged overall survival with this combination compared to historical chemotherapy results in similar patients.&nbsp;The upcoming Phase 3 trial, conducted globally across multiple sites, will enroll 462 participants. The primary endpoint is overall survival, while secondary measures include disease control rate, progression-free survival, objective response rate, and safety.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Jan_29_015db24b68.png" alt="IBRX sentiment and message volume Jan 29.png" width="1318" height="324"><figcaption>IBRX sentiment and message volume Jan 29 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘bullish’ for ImmunityBio on Wednesday, up from ‘neutral’ a day ago, while BeiGene’s sentiment shifted to ‘extremely bullish’ amid a spike in message volume.&nbsp;One user speculated that BeiGene could also become ImmunityBio’s global partner for bladder cancer treatments, suggesting another announcement might follow soon.&nbsp;<stembedurl>https://stocktwits.com/Dmck9/message/601987411</stembedurl>Another post predicted a 150% rally in the coming weeks.<stembedurl>https://stocktwits.com/Terrashae/message/601984996</stembedurl>ImmunityBio has been a closely watched stock among retail traders, with its Stocktwits following growing by nearly 43% in the past year despite a 10% decline in the stock’s price over the same period.&nbsp;Year to date, however, shares are up nearly 28%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as...

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

BeOne Medicines Ltd - ADR

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.71	--	--	N/A
Q2 '25	$0.32	$0.91	183.43%	BEAT
Q1 '25	-$0.53	$0.00	100.00%	BEAT
Q4 '24	-$1.04	-$1.43	-37.50%	MISSED
Q3 '24	--	-$1.15	--	N/A

ONC
BeiGene Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ONC News

ONC BeiGene Ltd - ADR